Alnylam gets EU approval for Amvuttra in heart disorder treatment

Hailshadow/iStock via Getty Images

• Alnylam Pharmaceuticals (NASDAQ:ALNY) said on Monday that the European Commission has approved its RNAi therapeutic, Amvuttra, to treat hereditary transthyretin amyloidosis in adults with cardiomyopathy.
• This adds a new indication for the drug, which was previously approved in March 2025